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Objectives. This study assessed whether treatment with a
beta-adrenergic blocking agent in addition to the use of the
angiotensin-converting enzyme (ACE) inhibitor captopril de-
creases cardiovascular mortality and morbidity in patients with
asymptomatic left ventricular dysfunction after myocardial infarc-
tion (MI) and whether the presence of neurohumoral activation at
the time of hospital discharge predicts the effects of beta-blocker
treatment in these patients.
Background. Both beta-blockers and ACE inhibitors have been
shown to have beneficial effects in patients with left ventricular
dysfunction but no overt heart failure after MI. These patients often
have persistent neurohumoral activation at the time of hospital
discharge, and one would expect that patients with activation of the
sympathetic nervous system derive the most benefit from treatment
with beta-blockers. However, beta-blockers are underutilized in this
high risk group of patients, and it is unknown whether their
beneficial effects are additive to those of ACE inhibitors.
Methods. We performed a retrospective analysis of data from
the Survival and Ventricular Enlargement (SAVE) study and its
neurohumoral substudy. The relations between beta-blocker use
at the time of randomization and neurohumoral activation and
the subsequent development of cardiovascular events were ana-
lyzed by use of Cox proportional hazards models controlling for
covariates.
Results. After adjustment for baseline imbalances, beta-blocker
use was associated with a significant reduction in risk of cardio-
vascular death (30%, 95% confidence interval [CI] 12% to 44%)
and development of heart failure (21%, 95% CI 3% to 36%), but
the reduction in recurrent MI (11%, 95% CI 13% to 31%) was not
significant. These reductions were independent of the use of
captopril. Beta-blockers were not found to have a greater effect in
patients with neurohumoral activation at the time of hospital
discharge.
Conclusions. The beneficial effects of beta-blocker use at the
time of hospital discharge in patients with asymptomatic left
ventricular dysfunction after MI appear to be additive to those of
captopril and other interventions known to improve prognosis.
Neurohumoral activation at the time of hospital discharge fails to
identify those patients who will derive the greatest benefit from
treatment with beta-blockers.
(J Am Coll Cardiol 1997;29:229–36)
q1997 by the American College of Cardiology
The Survival and Ventricular Enlargement (SAVE) study (1)
demonstrated that long-term therapy with the angiotensin-
converting enzyme (ACE) inhibitor captopril decreased mor-
tality and morbidity among survivors of myocardial infarction
(MI) who had left ventricular dysfunction in the absence of
overt heart failure. Because neurohumoral activation occurs in
a significant proportion of these patients at the time of hospital
discharge (2), and because blockade of the renin-angiotensin-
aldosterone system is one of the mechanisms of action of ACE
inhibitors, it can be hypothesized that blockade of the sympa-
thetic nervous system with beta-adrenergic blocking agents
would be beneficial as well in this patient population. However,
although the use of beta-blockers as secondary prevention is of
proven value in the population of postinfarction patients at
large (3), these agents are still relatively underutilized (4,5). In
particular, their prescription in patients with impaired left
ventricular function is too infrequent, probably because of fear
of precipitating or aggravating heart failure. This hesitation to
treat with beta-blockers persists and this despite evidence that
these high risk postinfarction patients have the most to gain in
absolute terms from such treatment (6–9). Indeed, left ven-
tricular dysfunction has been found (5,10) to be a predictor of
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failure to prescribe beta-blockers. Furthermore, it is unclear
whether these agents confer an additional benefit to the
patient with asymptomatic left ventricular dysfunction who is
already taking an ACE inhibitor.
In a previous analysis of the SAVE neurohumoral data (11),
we demonstrated that neurohumoral activation at the time of
hospital discharge after MI was associated with a higher risk of
subsequent cardiovascular events (11). In particular, activation
of the adrenergic system, as reflected by increased plasma
norepinephrine values, was associated with a poor prognosis.
Intuitively, one would expect those patients with elevated
plasma norepinephrine levels to benefit the most from beta-
blocker therapy, but there are no data that support this
supposition.
Therefore, we conducted a retrospective analysis of data
from the SAVE study to address two questions concerning
survivors of MI with left ventricular dysfunction in the absence
of overt heart failure: 1) Does treatment with a beta-blocker
have a beneficial effect on cardiovascular mortality and mor-
bidity in addition to and independently of the use of captopril?
2) Is there a relation between neurohumoral activation at the
time of hospital discharge and the subsequent effect of beta-
blockers?
Methods
Patients. The SAVE study enrolled 2,231 patients, of
whom 534 participated in a substudy to evaluate the degree
and prognostic significance of neurohumoral activation at the
time of hospital discharge after MI. The methods and results of
the main study and the neurohumoral substudy were reported
previously (1,2,11,12). Briefly, only patients with a left ventric-
ular ejection fraction #40% by radionuclide ventriculography
and without overt heart failure or heart failure requiring
vasodilator therapy were recruited and randomized to capto-
pril or placebo therapy commencing 3 to 16 days after MI.
Exclusion criteria were contraindications to the use of an ACE
inhibitor; concurrent medical problems, such as renal insuffi-
ciency (creatinine .2.5 mg/dl), severe valvular disease, refrac-
tory hypertension, malignancy or other conditions thought to
limit survival; geographic problems; or inability or unwilling-
ness to give informed consent. Patients with ischemic symp-
toms or markedly positive exercise test results were also
excluded unless cardiac catheterization and appropriate revas-
cularization procedures were conducted before randomization.
The average length of follow-up (6SD) for the surviving
patients was 426 10 months in the total SAVE population and
38 6 7 months in the group constituting the neurohumoral
substudy.
The patients taking part in the neurohumoral substudy
consented to have additional blood samples drawn before their
randomization (mean 12 days after MI), to measure plasma
renin activity and plasma concentrations of norepinephrine,
atrial natriuretic peptide, arginine vasopressin, epinephrine,
aldosterone and dopamine. An indwelling venous cannula was
inserted on the morning after an overnight fast, and the patient
had to rest in the supine position for 30 min before blood
sampling. The samples were centrifuged at 48C, frozen at
2808C and sent monthly to the central laboratory (Hoˆpital du
Sacre´-Coeur de Montre´al) packed in dry ice. All sample
transfers between peripheral and central laboratories took
,24 h. Samples that were delayed, hemolyzed or thawed were
not measured. Previously described neurohormone assays
(13,14) were used. To minimize the loss of activity, ANP levels
were measured as soon as the samples were received (15).
Activation of a neurohormone was considered present when
the plasma activity or level was equal to or higher than the
mean plus 1.96 times the standard deviation of 38 age-matched
control subjects without known disease and not taking medi-
cation (576 7 years; 14 women) (2). Blood samples from these
control subjects were obtained and handled in a manner
identical to that used for the SAVE patients.
End points. The end points studied were 1-year cardiovas-
cular mortality, total cardiovascular mortality, severe heart
failure, recurrent MI and the combined end point of total
cardiovascular mortality or severe heart failure or recurrent
MI, whichever occurred first. An independent committee
assessed and classified deaths as to whether they resulted from
cardiovascular disease. Severe heart failure was defined as heart
failure requiring hospital admission for management or clinical
deterioration requiring the use of open label ACE inhibition.
Recurrent MI was defined as a clinical MI by the participating
center or for fatal events by the mortality committee.
Data analysis. Information about beta-blocker use was
systematically obtained as part of the recruitment and
follow-up procedure of the SAVE study. Use of a beta-blocker
was optional and was left to the discretion of the treating
physician. Neither type nor dose of beta-blocker nor indication
for its use was recorded. Analysis was carried out on an
intention to treat basis: Depending on whether patients were
taking a beta-blocker at randomization, they were categorized
into the group using a beta-blocker or the group not using a
beta-blocker regardless of the patient’s postbaseline beta-
blocker exposure.
Baseline characteristics of different patient categories were
compared by use of the two-sample t test for continuous
variables and chi-square tests for categoric variables.
Cox proportional hazard models were used to analyze the
relations between beta-blocker use and subsequent end points
in the entire SAVE population as well as in the neurohumoral
subgroup. Relative risk (more precisely, relative hazard), 95%
confidence intervals and Wald chi-square and p values were
derived from the regression coefficients of the independent
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CI 5 confidence interval
MI 5 myocardial infarction
SAVE 5 Survival and Ventricular Enlargement study
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variables. First, a univariate analysis was performed with
beta-blocker use as the only independent variable. Then, nine
major independent variables (age, gender, history of previous
MI, diabetes mellitus, hypertension, left ventricular ejection
fraction, use of thrombolytic therapy, use of aspirin or warfa-
rin, and randomization to captopril) were added to the model,
and a multivariate analysis was conducted.
To compare the effect of beta-blockers on the development
of end points in patients with and without activation of a
particular neurohormone, the neurohumoral subgroup was
stratified according to the absence or presence of neurohu-
moral activation. Within each stratum, the score statistic of a
univariate Cox model with beta-blocker use as the independent
variable was used to assess differences in event-free survival
between patients receiving beta-blockers and those not receiv-
ing these agents for each type of end point. Survival curves
were generated by the Kaplan-Meier method. To determine
whether neurohumoral activation modifies the relation be-
tween beta-blocker use and subsequent end points, a multivar-
iate Cox model was used in the neurohumoral subgroup as a
whole, with beta-blocker use, dichotomized neurohormone
level (activation or not) and an interaction term as indepen-
dent variables. The interaction term was defined as the product
of the other two independent variables.
All statistical analyses were performed using the SAS and
the BMDP software packages. The reported probability values
are two-tailed, and a significance level of 0.05 was used.
Results
Patient characteristics. Table 1 shows the baseline charac-
teristics of the entire SAVE population as well as of the 534
patients in the neurohumoral substudy. The neurohumoral
substudy patients did not differ from the rest of the SAVE
population with respect to male/female ratio; history of MI or
diabetes; left ventricular ejection fraction; use of thrombolysis
and captopril; use of warfarin or aspirin; and peak creatine
kinase level. However, the patients in the neurohumoral
substudy, were slightly older, less often had hypertension and
underwent less revascularization procedures before random-
ization. The proportion of patients receiving beta-blocker
therapy in the neurohumoral subgroup and the proportion in
the remainder of the population were comparable (34% and
36% respectively, p 5 NS). Both in the entire SAVE popula-
tion and in the neurohumoral subgroup, patients using beta-
blockers had a higher incidence of hypertension and a higher
left ventricular ejection fraction and were more often treated
with aspirin or warfarin. Furthermore, in the entire SAVE
population, but not in the neurohumoral subgroup, patients
taking beta-blockers were younger, were less likely to have had
a previous MI, received thrombolytic agents more frequently
and underwent less revascularization procedures before ran-
domization. In the neurohumoral subgroup, neurohormone
Table 2. Neurohumoral Variables*
No BBs BBs
Plasma renin activity (ng/ml per liter) (n 5 506) 3.12 6 4.0 2.60 6 3.0
% activated 22 21
Plasma NE (pg/ml) (n 5 506) 297 6 189 300 6 198
% activated 24 23
Plasma ANP (pg/ml) (n 5 508) 77 6 79 73 6 69
% activated 66 66
Plasma AVP (pg/ml) (n 5 506) 2.1 6 8.1 1.4 6 2.5
% activated 30 27
Plasma epinephrine (pg/ml) (n 5 505) 36.1 6 30.3 36.3 6 23.4
% activated 9 9
Plasma aldosterone (ng/dl) (n 5 504) 27.7 6 30.8 25.5 6 20.1
% activated 27 25
Plasma dopamine (pg/ml) (n 5 496) 27.7 6 25.0 27.9 6 23.5
% activated 26 26
*p 5 NS for all comparisons. Data presented are mean values 6 SD or
percent of patients. Activated 5 a value 1.96 SD above the mean level in
age-matched control subjects; ANP5 atrial natriuretic peptide; AVP5 arginine
vasopressin; BBs 5 beta-blockers; NE 5 norepinephrine.
Table 1. Baseline Characteristics









(n 5 182) p Value*
Age (yr) 606 10 58 6 11 ,0.001 61 6 11 59 6 10 NS 0.039
Male gender 82 83 NS 83 79 NS NS
Previous MI 37 32 0.016 35 34 NS NS
Diabetes 23 21 NS 20 20 NS NS
Hypertension 35 42 0.003 26 38 0.006 ,0.001
LVEF 30 6 7 32 6 6 ,0.001 30 6 7 33 6 6 ,0.001 NS
Thrombolysis 33 38 0.015 32 33 NS NS
Captopril 50 50 NS 51 49 NS NS
Aspirin or warfarin 75 80 0.018 74 85 0.003 NS
Highest serum CK (U/liter) 2,5986 2,462 2,594 6 2,168 NS 2,590 6 2,275 2,547 6 1,911 NS NS
Revascularization before randomization 25 21 0.016 13 13 NS ,0.001
*No beta-blockers (BBs) versus beta-blockers. †Neurohumoral subgroup versus remainder of SAVE population. Data presented are mean value 6 SD or percent
of patients. CK 5 creatine kinase; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; SAVE 5 Survival and Ventricular Enlargement study.
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levels and the proportion of patients with activation of a
specific neurohormone were similar for patients using beta-
blockers and those not using beta-blockers (Table 2).
Effects of beta-blocker use on end points. The univariate
relations between beta-blocker use and subsequent end points
are shown in Table 3. In the entire SAVE population, the use
of beta-blockers was significantly associated with lower 1-year
cardiovascular mortality, total cardiovascular mortality, occur-
rence of severe heart failure and occurrence of the combined
end point. Although patients using beta-blockers had a lower
risk of developing a recurrent MI, this risk reduction did not
reach statistical significance. Although a qualitatively and
quantitatively similar reduction in risk associated with beta-
blocker use was noted in the neurohumoral subgroup, because
of the smaller number of patients and thus wider confidence
intervals, only the reductions of 1-year cardiovascular mortal-
ity, total cardiovascular mortality and development of severe
heart failure were statistically significant.
More important, when the use of beta-blockers was consid-
ered along with age, gender, history of previous MI, hyperten-
sion, diabetes mellitus, left ventricular ejection fraction, use of
thrombolysis, randomization to captopril and use of aspirin or
warfarin in multivariate analyses (Table 4) in the total SAVE
population, the influence of beta-blocker use at randomization
remained significant. However, the reductions in relative risk
associated with the use of beta-blockers were smaller, suggest-
ing that beta-blocker effectiveness may be associated with
covariates and that imbalances existed in the use of beta-
blockers. In the neurohumoral subpopulation, despite being
qualitatively and quantitatively similar to those observed in the
total SAVE population, the reductions in risk associated with
the use of beta-blockers were not statistically significant,
perhaps because of the small number of events in proportion
to the number of independent variables used in the multivar-
iate analyses.
Role of neurohumoral activation. Table 5 shows the effects
of beta-blockers on cardiovascular events in the neurohumoral
subgroup according to the absence or presence of neurohu-
moral activation. For the most part, beta-blockers were not
found to have a greater effect in patients with neurohumoral
activation. On the contrary, with the exception of atrial natri-
uretic peptide, beta-blockers appeared to have less or even no
effect in the presence of neurohumoral activation and to be
most effective in patients without neurohumoral activation, as
illustrated in Figure 1 for norepinephrine. Table 6 shows that
a statistically significant interaction between the use of beta-
blockers and neurohumoral activation could be found only in
the relations between total cardiovascular mortality and acti-
vation of norepinephrine and aldosterone. In both cases the
regression coefficient of the interaction term has a positive
sign, meaning that neurohumoral activation reduces the effi-
cacy of beta-blockers.
Discussion
The present study demonstrates that, irrespective of ran-
domization to captopril, survivors of MI who have asymptom-
atic left ventricular dysfunction and who are taking a beta-
Table 3. Univariate Cox Proportional Hazards Analysis of Relations Between Beta-Blocker Use at Baseline and Individual End Points





















1-yr CV mortality 11.9 7.1 12.36 ,0.001 0.58 (0.43–0.79) 11.1 5.5 4.26 0.039 0.48 (0.24–0.96)
Total CV mortality 22.1 13.1 25.43 ,0.001 0.57 (0.45–0.71) 19.0 10.4 6.55 0.011 0.51 (0.31–0.86)
Severe HF 22.6 16.5 14.24 ,0.001 0.68 (0.55–0.83) 19.0 12.6 4.25 0.039 0.61 (0.38–0.98)
Recurrent MI 14.3 12.3 2.68 NS 0.82 (0.64–1.04) 11.7 9.9 0.62 NS 0.80 (0.46–1.39)
CV mortality or severe HF
or recurrent MI
39.7 29.8 18.17 ,0.001 0.72 (0.62–0.84) 32.4 26.9 2.25 NS 0.77 (0.55–1.08)
CI 5 confidence interval; CV 5 cardiovascular; HF 5 heart failure; RR 5 relative risk; other abbreviations as in Table 1.
Table 4. Multivariate Cox Proportional Hazards Analysis of Relations Between Beta-Blocker Use at
Baseline and Individual End Points













1-yr CV mortality 3.78 0.052 0.74 (0.54–1.00) 0.89 NS 0.71 (0.34–1.46)
Total CV mortality 9.35 0.002 0.70 (0.56–0.88) 1.35 NS 0.73 (0.43–1.24)
Severe HF 5.09 0.024 0.79 (0.64–0.97) 3.22 NS 0.63 (0.38–1.04)
Recurrent MI 0.96 NS 0.89 (0.69–1.13) 0.10 NS 0.91 (0.51–1.62)
CV mortality or severe HF
or recurrent MI
6.12 0.013 0.82 (0.71–0.96) 1.06 NS 0.83 (0.59–1.18)
Abbreviations as in Tables 1 and 3.
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blocker at the time of hospital discharge have a better
prognosis than those who are not using one of these agents.
This association between beta-blocker use and better progno-
sis is independent of nine other factors known to influence
prognosis after MI. In addition, neurohumoral activation does
not clearly identify patients who would derive the most benefit
from treatment with a beta-blocker. Indeed, in this analysis,
patients with elevated plasma norepinephrine levels appeared
to derive little or no benefit from treatment with beta-blockers,
the benefits of beta-blockers being limited to those without
activation of plasma norepinephrine.
Beta-blockers and subsequent mortality and morbidity.
This study demonstrates that the long-term use of beta-
blockers in patients who have had a MI and who have left
ventricular dysfunction is associated with a decrease in cardio-
vascular mortality and a decrease in the incidence of severe
heart failure. These reductions in risk are independent of other
known risk factors for these same end points. Several large,
randomized, placebo-controlled trials (3) performed in the late
1970s to mid-1980s showed that long-term treatment with
beta-blockers reduces mortality by ;25% in patients who
sustained a MI. In these trials the relative mortality reduction
Table 5. Effects of Beta-Blockers According to Absence or Presence of Neurohumoral Activation in the Neurohumoral Subgroup*

















Renin 27/262 (10.3%) 5/134 (3.7%) 0.35 (0.13–0.91) 5.083 0.024 11/75 (14.7%) 5/35 (14.3%) 0.96 (0.33–2.75) 0.007 NS
NE 27/258 (10.5%) 4/128 (3.1%) 0.29 (0.10–0.82) 6.184 0.013 10/81 (12.4%) 5/39 (12.8%) 1.04 (0.35–3.04) 0.005 NS
ANP 5/116 (4.3%) 3/58 (5.2%) 1.20 (0.29–5.03) 0.063 NS 33/223 (14.8%) 7/111 (6.3%) 0.41 (0.18–0.92) 5.021 0.025
AVP 22/235 (9.4%) 7/124 (5.7%) 0.59 (0.25–1.39) 1.472 NS 15/102 (14.7%) 3/45 (6.7%) 0.43 (0.12–1.49) 1.883 NS
Epinephrine 31/306 (10.1%) 8/152 (5.3%) 0.51 (0.23–1.10) 3.048 0.081 6/32 (18.8%) 1/15 (6.7%) 0.34 (0.04–2.84) 1.083 NS
Aldosterone 24/247 (9.7%) 4/125 (3.2%) 0.32 (0.11–0.91) 5.063 0.024 14/90 (15.6%) 6/42 (14.3%) 0.93 (0.36–2.42) 0.023 NS
Dopamine 25/246 (10.2%) 4/122 (3.3%) 0.31 (0.11–0.90) 5.212 0.022 12/85 (14.1%) 4/43 (9.3%) 0.65 (0.21–2.02) 0.563 NS
Total CV mortality
Renin 42/262 (16%) 11/134 (8.2%) 0.49 (0.25–0.94) 4.767 0.029 22/75 (29.3%) 7/35 (20%) 0.66 (0.28–1.55) 0.921 NS
NE 46/258 (17.8%) 8/128 (6.3%) 0.32 (0.15–0.69) 9.627 0.002 18/81 (22.2%) 9/39 (23.1%) 1.08 (0.48–2.41) 0.032 NS
ANP 9/116 (7.8%) 4/58 (6.9%) 0.89 (0.27–2.88) 0.04 NS 56/223 (25.1%) 14/111 (12.6%) 0.46 (0.26–0.83) 6.951 0.008
AVP 38/235 (16.2%) 11/124 (8.9%) 0.53 (0.27–1.04) 3.512 0.061 25/102 (24.5%) 7/45 (15.6%) 0.59 (0.26–1.37) 1.529 NS
Epinephrine 55/306 (18%) 16/152 (10.5%) 0.56 (0.32–0.97) 4.378 0.036 9/32 (28.1%) 1/15 (6.7%) 0.23 (0.03–1.85) 2.249 NS
Aldosterone 43/247 (17.4%) 8/125 (6.4%) 0.34 (0.16–0.72) 8.732 0.003 22/90 (24.4%) 10/42 (23.8%) 1.02 (0.48–2.17) 0.003 NS
Dopamine 43/246 (17.5%) 10/122 (8.2%) 0.44 (0.22–0.87) 5.935 0.015 20/85 (23.5%) 6/43 (14%) 0.56 (0.23–1.40) 1.584 NS
Severe HF
Renin 41/262 (15.7%) 17/134 (12.7%) 0.74 (0.42–1.30) 1.133 NS 24/75 (32%) 6/35 (17.1%) 0.48 (0.20–1.17) 2.735 0.098
NE 43/258 (16.7%) 14/128 (10.9%) 0.59 (0.32–1.07) 3.075 0.079 21/81 (25.9%) 9/39 (23.1%) 0.85 (0.39–1.87) 0.155 NS
ANP 13/116 (11.2%) 4/58 (6.9%) 0.58 (0.19–1.79) 0.908 NS 52/223 (23.3%) 19/111 (17.1%) 0.65 (0.38–1.09) 2.672 NS
AVP 39/235 (16.6%) 15/124 (12.1%) 0.67 (0.37–1.22) 1.754 NS 25/102 (24.5%) 8/45 (17.8%) 0.65 (0.29–1.45) 1.118 NS
Epinephrine 57/306 (18.6%) 18/152 (11.8%) 0.57 (0.34–0.97) 4.409 0.036 7/32 (21.9%) 5/15 (33.3%) 1.40 (0.45–4.43) 0.34 NS
Aldosterone 41/247 (16.6%) 14/125 (11.2%) 0.59 (0.32–1.09) 2.881 0.090 24/90 (26.7%) 9/42 (21.4%) 0.79 (0.37–1.71) 0.353 NS
Dopamine 46/246 (18.7%) 18/122 (14.8%) 0.71 (0.41–1.22) 1.558 NS 15/85 (17.7%) 5/43 (11.6%) 0.62 (0.23–1.71) 0.863 NS
Recurrent MI
Renin 27/262 (10.3%) 16/134 (11.9%) 1.11 (0.60–2.07) 0.109 NS 12/75 (16%) 2/35 (6%) 0.33 (0.07–1.48) 2.328 NS
NE 28/258 (10.9%) 14/128 (10.9%) 0.96 (0.50–1.81) 0.02 NS 10/81 (12.4%) 4/39 (10.3%) 0.80 (0.25–2.55) 0.147 NS
ANP 19/116 (16.4%) 5/58 (8.6%) 0.51 (0.19–1.37) 1.864 NS 20/223 (9%) 13/111 (11.7%) 1.26 (0.62–2.53) 0.411 NS
AVP 20/235 (8.5%) 11/124 (8.9%) 1.02 (0.49–2.13) 0.003 NS 19/102 (18.6%) 7/45 (15.6%) 0.77 (0.32–1.82) 0.366 NS
Epinephrine 31/306 (10.1%) 18/152 (11.8%) 1.13 (0.63–2.01) 0.163 NS 7/32 (21.9%) 0/15 (0%) 0.00 (0.00–`) 3.408 0.065
Aldosterone 26/247 (10.5%) 13/125 (10.41%) 0.93 (0.48–1.82) 0.041 NS 13/90 (14.4%) 5/42 (11.9%) 0.80 (0.28–2.24) 0.184 NS
Dopamine 25/246 (10.2%) 17/122 (13.9%) 1.32 (0.72–2.45) 0.802 NS 11/85 (12.9%) 1/43 (2.3%) 0.16 (0.02–1.24) 4.049 0.044
CV mortality or severe HF
or recurrent MI
Renin 74/262 (28.2%) 36/134 (26.9%) 0.91 (0.61–1.35) 0.238 NS 36/75 (48%) 12/35 (34.3%) 0.63 (0.33–1.21) 1.948 NS
NE 78/258 (30.2%) 30/128 (23.4%) 0.72 (0.47–1.10) 2.287 NS 32/81 (39.5%) 17/39 (43.6%) 1.05 (0.58–1.89) 0.022 NS
ANP 29/116 (25%) 10/58 (17.2%) 0.67 (0.33–1.37) 1.1217 NS 82/223 (36.8%) 38/111 (34.2%) 0.87 (0.59–1.27) 0.536 NS
AVP 64/235 (27.2%) 32/124 (25.8%) 0.91 (0.59–1.39) 0.199 NS 45/102 (44.1%) 16/45 (35.6%) 0.73 (0.41–1.28) 1.215 NS
Epinephrine 97/306 (31.7%) 42/152 (27.6%) 0.82 (0.57–1.17) 1.197 NS 13/32 (40.6%) 5/15 (33.3%) 0.78 (0.28–2.19) 0.226 NS
Aldosterone 71/247 (28.7%) 31/125 (24.8%) 0.80 (0.52–1.21) 1.118 NS 40/90 (44.4%) 17/42 (40.5%) 0.88 (0.50–1.55) 0.212 NS
Dopamine 77/246 (31.3%) 35/122 (28.7%) 0.86 (0.58–1.29) 0.534 NS 30/85 (35.3%) 1/43 (25.6%) 0.67 (0.33–1.33) 1.347 NS
*Relative risks, score statistics and p values calculated from univariate Cox models. †Beta-blockers (BBs) versus no beta-blockers. Data presented are number (%)
of patients, unless otherwise indicated. Other abbreviations as in Tables 1 to 3.
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in patients with left ventricular dysfunction was comparable to
that observed in the global population (6–9). Consequently,
because of their higher than average mortality, the survival
benefit of long-term beta-blocker treatment in absolute num-
bers is even more impressive in these high risk patients.
Indeed, a report of the American College of Cardiology/
American Heart Association Task Force (16) considered long-
term beta-blockade in “all but low risk patients who do not
have a clear contraindication to beta-blockade” to be a class I
recommendation, and it is very unlikely that other randomized
trials of long-term beta-blockade specifically targeted to high
risk postinfarction patients will ever be performed in the
future. However, since the introduction of beta-blockers, nu-
merous other interventions that improve survival after MI have
become standard practice. Whether the beneficial effects of
long-term treatment with beta-blockers are additive to the
benefits of these newer interventions or have become less
important has, to our knowledge, never been studied before
the present analysis.
In the SAVE study, a substantial proportion of the patients
were treated with thrombolytic agents, aspirin or warfarin or
had a revascularization procedure before randomization to be
eligible, and 50% by design were using captopril. Despite these
interventions, an analysis using a multivariate model to adjust
for possible differences in important prognostic variables be-
tween patients taking and not taking beta-blockers indicates
that beta-blocker treatment was associated with a 26% reduc-
tion in 1-year cardiovascular mortality and a 30% reduction in
cardiovascular mortality over the length of the study. These
results are consistent with the findings of the randomized trials
and suggest that long-term beta-blocker treatment improves
survival in postinfarction patients with asymptomatic left ven-
tricular dysfunction in addition to, and independent of, more
recently proven beneficial interventions, including ACE inhi-
bition, and remains a valuable tool in current postinfarction
care.
We found that the use of beta-blockers was associated with
a 21% lower risk of developing severe heart failure. However,
because this was not a prospective, randomized study and
because variables increasing the risk of developing heart
failure may have been missed despite our best efforts, it is
difficult to be certain whether the observed risk reduction was
the result of beta-blocker treatment or of patient selection.
This is particularly true when one considers that previous
prospective, randomized studies of beta-blocker use in postin-
farction patients have not demonstrated this type of beneficial
effect (3). Nevertheless, this observation could help to alleviate
the fear of increasing the risk of heart failure when prescribing
beta-blockers to postinfarction patients with asymptomatic left
ventricular dysfunction.
In the present study the reduction in risk of recurrent MI
associated with the use of beta-blockers was small (18%) and
not statistically significant. This risk reduction was even smaller
(11%) when other risk factors were accounted for in a multi-
variate analysis. These results are at odds with previous
prospective, randomized studies (3) in which the use of
beta-blockers resulted in a significant decrease (;25%) in the
rate of recurrent MI. The smaller risk reduction observed in
the SAVE study may be the result of the fact that patients in
SAVE received other medications that reduce the reinfarction
rate but had not yet been used in earlier prospective random-
Figure 1. Survival curves as a function of activation of norepinephrine
and use of beta-blockers.
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ized studies. Also, to be eligible for the SAVE study, 27% of
the patients had to undergo revascularization procedures
before randomization because of recurrent ischemia or posi-
tive exercise test results. These interventions may have reduced
the effect of beta-blocker treatment on the risk of recurrent MI
and might explain these discrepant results. Furthermore, be-
cause recurrent MI was the least frequent end point with the
smallest difference in incidence between patients taking and
not taking beta-blockers, the sample size may have been too
small for the observed difference to reach statistical signifi-
cance.
When comparing our results with those of past large,
randomized trials (3), it must be kept in mind that the evidence
for the beneficial effects and tolerability of beta-blockers in
survivors of MI who have left ventricular dysfunction is derived
from post hoc subgroup analysis (6,7) or meta-analysis (8,9) of
the trial data. Several of these trials included varying numbers
of patients with a history of compensated or mild congestive
heart failure or with symptoms and signs suggesting left
ventricular dysfunction, but left ventricular function was never
directly measured. In contrast, the SAVE population was made
up exclusively of postinfarction patients satisfying a uniform
and objective definition of left ventricular dysfunction (ejection
fraction #40% by radionuclide angiography). However, in the
present retrospective analysis, patients were not randomized to
beta-blocker use, and some form of selection bias that could
not be accounted for in our multivariate analysis cannot be
ruled out.
Role of neurohumoral activation. Neurohumoral activa-
tion has been shown to be an independent predictor of
mortality in the SAVE population (11), in other studies of
postinfarction patients (17) and in studies of patients with
chronic congestive heart failure (18,19). Among patients with
chronic congestive heart failure, those who have the most
marked neurohumoral activation appear to derive the greatest
survival benefit from treatment with ACE inhibitors (19,20).
In the SAVE neurohumoral substudy, captopril was asso-
ciated with the same relative benefit regardless of the absence
or presence of neurohumoral activation, but because patients
with neurohumoral activation were at greater absolute risk,
they experienced the greatest benefit in absolute terms (11). In
the same SAVE population, neurohumoral activation ap-
peared to be of little use in identifying patients who would
benefit the most from long-term treatment with a beta-blocker.
Furthermore, when an interaction between the use of beta-
blockers and activation of norepinephrine and aldosterone was
found, it was a negative one. This observation indicates that in
these instances neurohumoral activation was associated with
less beneficial effects of beta-blockers. The reasons for these
surprising findings are not clear and may be due to one or more
of the following factors:
1. The dose of beta-blocker used in the present study was
not recorded, and thus it is possible that the dose of beta-
blocker used was inadequate to block the deleterious effects of
norepinephrine in patients with activation of the sympathetic
nervous system. This is particularly true when one considers
that the plasma norepinephrine concentration is an imperfect
measure of adrenergic activity and may underestimate cardiac
sympathetic activation, which is known to be pronounced in
patients with severe left ventricular dysfunction (21).
2. A single determination of neurohumoral activity done at
rest during the first weeks after MI is an imperfect reflection of
long-term neurohumoral activation after MI and may inade-
quately reflect the dynamic nature of neurohumoral distur-
bances in these patients (22). For example, patients who
develop progressive left ventricular dilation are known to be at
higher risk of developing heart failure (23) and thus of
increasing neurohumoral activation, whereas those without
ventricular dilation may have an attenuation of neurohumoral
activation.
3. Although the population of the neurohumoral substudy
of SAVE is thus far the largest cohort of postinfarction
patients for whom neurohumoral data are available, the pos-
sibility of low statistical power due to inadequate sample size
must be considered. This is especially true because patients
needed to be classified into four subgroups for the analyses
Table 6. Cox Proportional Hazards Analysis of Interaction Between












Renin 2.72 (0.65–11.28) 0.9993 1.89 NS
NE 3.60 (0.79–16.48) 1.2806 2.79 NS
ANP 0.34 (0.07–1.76) 21.0808 1.65 NS
AVP 0.72 (0.16–3.22) 20.3342 0.19 NS
Epinephrine 0.64 (0.07–6.12) 20.4436 0.15 NS
Aldosterone 2.94 (0.71–12.23) 1.0775 2.19 NS
Dopamine 2.08 (0.44–9.77) 0.7314 0.86 NS
Total CV mortality
Renin 1.38 (0.47–4.07) 0.3249 0.35 NS
NE 3.18 (1.06–9.52) 1.1556 4.26 0.039
ANP 0.53 (0.14–1.97) 20.6392 0.91 NS
AVP 1.12 (0.38–3.27) 0.1108 0.04 NS
Epinephrine 0.39 (0.05–3.35) 20.9323 0.73 NS
Aldosterone 2.95 (1.02–8.53) 1.0803 3.97 0.046
Dopamine 1.27 (0.41–3.98) 0.2392 0.17 NS
Severe HF
Renin 0.64 (0.22–1.84) 20.4503 0.69 NS
NE 1.47 (0.55–3.94) 0.3835 0.58 NS
ANP 1.10 (0.32–3.79) 0.0945 0.02 NS
AVP 0.98 (0.36–2.65) 20.0192 0.00 NS
Epinephrine 2.49 (0.70–8.82) 0.9122 2.00 NS
Aldosterone 1.32 (0.50–3.50) 0.2762 0.31 NS
Dopamine 0.86 (0.27–2.72) 20.1484 0.06 NS
Recurrent MI
Renin 0.30 (0.06–1.53) 21.1978 2.1 NS
NE 0.86 (0.23–3.22) 20.1549 0.05 NS
ANP 2.51 (0.75–8.41) 0.9204 2.22 NS
AVP 0.75 (0.24–2.35) 20.2817 0.24 NS
Epinephrine 0.00 (0.00–`) 211.005 0.01 NS
Aldosterone 0.85 (0.25–2.91) 20.1602 0.07 NS
Dopamine 0.13 (0.01–1.08) 22.0623 3.57 NS
Coeff 5 coefficient; other abbreviations as in Tables 2 and 3.
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shown in Table 5. Nevertheless, our findings indicate a nega-
tive association between increased norepinephrine levels and
the beneficial effects of beta-blockers. Thus, although the
significance of this negative association can be questioned, it is
unlikely that a positive association could be found had a
greater sample size been evaluated.
4. The lack of effect of beta-blockers in patients with
neurohumoral activation could also be due to differences in
patient characteristics rather than differences in treatment.
However, the small number of events precluded meaningful
multivariate analysis to adjust for eventual differences in
patient characteristics.
5. Neurohumoral activation may be a marker for severity of
disease only and may be unrelated to the actual beneficial
effects of beta-blockers, which relate primarily to their effects
on improving excitation–contraction, calcium transport and
heart rate slowing (24).
Conclusions. The present retrospective analysis of the
SAVE data provides strong support for the persistent value of
beta-blocker treatment in the current management of MI in
addition to more recently proven beneficial measures, such as
use of aspirin and ACE inhibitors, especially in the high risk
group of patients with asymptomatic left ventricular dysfunc-
tion.
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